DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

ISRG·Intuitive Surgical, Inc.

$.
+. (+.%)
After Hours
High
$414.58
Open
$407.62
Market Cap
145.32B
52W High
$603.88
Low
$406.50
P. Close
$407.25
P/E
48.78
52W Low
$396.68
Fwd P/E
34.54
DailyIQ Est.
$592.19
Technical Score (1D)
27
SELL
News Sentiment
47
MIXED
The latest valuation analysis shows Intuitive Surgical’s discounted cash‑flow value aligns with its current market price, yet earnings multiples remain elevated, suggesting a premium that could be unsustainable if margin or competitive risks materialize. A voluntary recall of Da Vinci system components for an E‑brake pin defect has already weighed on short‑term share momentum, underscoring regulatory and operational risks that could dampen earnings if the recall extends. Analysts expect Q2 EPS of $2.48 and revenue of $2.81 billion, both up 13–15% YoY, and full‑year guidance of $10.41 EPS and $11.72 billion revenue, providing a near‑term earnings backdrop that traders will scrutinize for confirmation of growth. Evercore has trimmed its price target to $430 from $480, citing valuation concerns and competitive pressure, which may temper bullish sentiment if the company’s upside potential is perceived as limited. Options market pricing indicates a 68% probability that ISRG will finish between $280 and $610 over the next year, reflecting a wide range of upside and downside expectations that could translate into heightened volatility in the coming days. BMO Capital has initiated coverage with an Outperform rating and a $518 target, emphasizing the firm’s leadership in robotic surgery and projected revenue and margin expansion, which could attract new passive flows if the rating gains traction. The company’s focus on expanding into appendectomy procedures is still constrained by reimbursement limits, meaning near‑term adoption will likely remain modest until clinical evidence and payer policies evolve. Given the recent recall, the upcoming earnings release, and the divergent analyst targets, traders should monitor how ISRG addresses the recall, whether Q2 guidance aligns with expectations, and any updates on competitive dynamics or regulatory approvals that could shift the valuation narrative.
Earnings Summary
Intuitive Surgical (ISRG) is a medical technology company that develops and sells the da Vinci Surgical System and the Ion endoluminal system, positioning itself as a leader in minimally invasive robotic surgery and diagnostic procedures. The company operates in the healthcare sector, specifically within medical instruments and supplies, and relies on a global direct‑sales model to deliver its products and support services to hospitals worldwide. In the most recent two quarters, ISRG reported Q4 2025 revenue of $2.866 billion and EPS of $2.53, up from Q1 2026 revenue of $2.770 billion and EPS of $2.50. Compared to the preceding two quarters—Q2 2025 revenue $2.440 billion, EPS $2.19 and Q3 2025 revenue $2.505 billion, EPS $2.40—both revenue and EPS have accelerated, with year‑over‑year revenue growth of roughly 19 % and EPS growth of about 14 %. The company has consistently beat analyst estimates, posting earnings per share above forecasts in six of the last seven quarters, and has maintained a strong revenue trajectory. Over the past several years, ISRG’s YoY revenue growth has trended upward, moving from $2.413 billion in Q4 2024 to $2.866 billion in Q4 2025, while EPS has risen from $2.21 to $2.53, reflecting disciplined cost management and expanding procedure volumes. The company’s earnings history shows a pattern of robust revenue growth coupled with margin expansion, even as it navigates competitive pressures and regulatory scrutiny. Recent market commentary highlights a 68 % probability that ISRG will finish between $280 and $610 over the next year, driven by strong Q4 execution and a 17 % jump in procedure volume, while noting persistent headwinds. BMO Capital’s Outperform rating and $518 price target underscore confidence in continued revenue expansion and margin improvement, though Evercore’s price target cut to $430 signals caution amid reimbursement constraints for appendectomy procedures. Investors should watch for the next earnings release to confirm guidance on procedure volume growth, margin trends, and any updates on regulatory approvals or reimbursement policy changes, as these factors will shape the company’s valuation and market perception in the coming quarter.

EPS

EstBeatMiss
$1.61$1.87$2.13$2.39$2.65Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.50 - -
Q1'26$2.11$2.50+18.7%
Q4'25$2.30$2.53+9.8%
Q3'25$1.99$2.40+20.7%
Q2'25$1.92$2.19+14.1%
Q1'25$1.73$1.81+4.4%

Revenue

EstBeatMiss
$2.2B$2.4B$2.6B$2.8B$3.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.9B - -
Q1'26$2.6B$2.8B+5.8%
Q4'25$2.8B$2.9B+2.4%
Q3'25 - $2.5B -
Q2'25 - $2.4B -
Q1'25 - $2.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ISRG Stock Snapshot

ISRG is currently trading at $407.51, giving Intuitive Surgical, Inc. a market cap of 145.32B and a P/E ratio of 48.8. Today's range spans $406.50–$414.58, with shares opening at $407.62 and moving up $0.26 (0.1%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 47/100.

Over the past year ISRG has traded between $396.68 and $603.88 - the current price is +2.7% off the 52-week low and -32.5% from the high. 41 analysts cover the stock with a Buy consensus and a mean 12-month target of $561.84 (range $366.00–$750.00), implying upside of +37.9%.

Sector rotation is working against ISRG - large-cap, Healthcare, 145.32B market cap. Technical score 27/100 (SELL), sentiment neutral (47/100), price $407.51 (near 52-week lows). (P/E: 48.8) When capital rotates out of a sector, large-cap names with bearish technicals are the first to absorb the selling. Annual range $396.68–$603.88 frames where the next potential demand zone resides.

When a large-cap Healthcare name with 145.32B in capitalization prints a SELL signal (27/100) alongside neutral news sentiment (47/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $407.51 (near 52-week lows in the $396.68–$603.88 range), the structural support levels are where that sponsorship question gets answered.